Bioinformatic Identification of Genomic Instability-associated LncRNAs Signatures for Improving the Clinical Outcome of Cervical Cancer by a Prognostic Model
Authors
Affiliations
The research is executed to analyze the connection between genomic instability-associated long non-coding RNAs (lncRNAs) and the prognosis of cervical cancer patients. We set a prognostic model up and explored different risk groups' features. The clinical datasets and gene expression profiles of 307 patients have been downloaded from The Cancer Genome Atlas database. We established a prognostic model that combined somatic mutation profiles and lncRNA expression profiles in a tumor genome and identified 35 genomic instability-associated lncRNAs in cervical cancer as a case study. We then stratified patients into low-risk and high-risk groups and were further checked in multiple independent patient cohorts. Patients were separated into two sets: the testing set and the training set. The prognostic model was built using three genomic instability-associated lncRNAs (AC107464.2, MIR100HG, and AP001527.2). Patients in the training set were divided into the high-risk group with shorter overall survival and the low-risk group with longer overall survival (p < 0.001); in the meantime, similar comparable results were found in the testing set (p = 0.046), whole set (p < 0.001). There are also significant differences in patients with histological grades, FIGO stages, and different ages (p < 0.05). The prognostic model focused on genomic instability-associated lncRNAs could predict the prognosis of cervical cancer patients, paving the way for further research into the function and resource of lncRNAs, as well as a key approach to customizing individual care decision-making.
Wen Y, Liu Q, Xu W Exp Ther Med. 2025; 29(2):36.
PMID: 39776890 PMC: 11705229. DOI: 10.3892/etm.2024.12786.
Zheng J, Huang B, Xiao L, Wu M PeerJ. 2024; 12:e17035.
PMID: 38410799 PMC: 10896078. DOI: 10.7717/peerj.17035.
Multi-Omics Mining of lncRNAs with Biological and Clinical Relevance in Cancer.
Salido-Guadarrama I, Romero-Cordoba S, Rueda-Zarazua B Int J Mol Sci. 2023; 24(23).
PMID: 38068923 PMC: 10706612. DOI: 10.3390/ijms242316600.
LncmiRHG-MIR100HG: A new budding star in cancer.
Wu Y, Wang Z, Yu S, Liu D, Sun L Front Oncol. 2022; 12:997532.
PMID: 36212400 PMC: 9544809. DOI: 10.3389/fonc.2022.997532.